Posted by Michael Wonder on 03 Oct 2023
Oxford BioTherapeutics announces partner Boehringer Ingelheim received US FDA fast track designation for BI 764532 for the treatment of extensive stage small cell lung cancer and extrapulmonary neuroendocrine cancers
3 October 2023 - BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein.
Oxford BioTherapeutics today announces that the US FDA has granted fast track designation to BI 764532 for the treatment of extensive stage small cell lung cancer whose disease has progressed following at least two prior lines of treatment including platinum-based chemotherapy, and of advanced or metastatic extrapulmonary neuroendocrine carcinomas whose disease has progressed following at least one prior line of treatment including platinum-based chemotherapy.
